ABIODUN OLATUBOSUN: Open Payments
NPI 1215531678 · BLOOMFIELD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 48 payments from 9 companies in 2025. Trend: 2023 $921 · 2024 $1,083 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $330 |
| Otsuka America Pharmaceutical, Inc. | 10 | $203 |
| Janssen Pharmaceuticals, Inc | 8 | $144 |
| E.R. Squibb & Sons, L.L.C. | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| ABBVIE INC. | 2 | $38 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| Lundbeck LLC | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
Products named: ARISTADA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, COBENFY, REXULTI, VRAYLAR, INGREZZA.
Industry payments across NJ — which companies pay providers there.
